Advertisement

Topics

Pre-clinical collaboration formed between Nanobiotix & Providence Cancer Institute

07:13 EST 11 Jan 2018 | EPM Magazine

Nanobiotix, a late clinical-stage nanomedicine company, has started a pre-clinical collaboration with the Providence Cancer Institute to study NBTXR3 — a nanoparticle designed for direct injection into cancerous tumours and activation by radiotherapy

Related Biotechnology, Pharmaceutical and Healthcare News

Original Article: Pre-clinical collaboration formed between Nanobiotix & Providence Cancer Institute

NEXT ARTICLE

More From BioPortfolio on "Pre-clinical collaboration formed between Nanobiotix & Providence Cancer Institute"

Quick Links
Advanced Search | Login | Subscribe | RSS

Quick Search
Advertisement
 

Relevant Topics

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...


News Quicklinks

Search Biotech, Medical and Healthcare News

Popular Biotech, Medical and Healthcare News

Biotech News by Article Type

BioPortfolio Bloggers

Publishing Your News on BioPortfolio

Recent Visitor News Searches


BioPortfolio Limited Social Media
Publish Content Agreements
Tools Help

HON Code certificate This site complies with the HONcode standard for trustworthy health information:
Verify here.

The information provided by BioPortfolio.com is not a substitute for professional medical advice, diagnosis or treatment. The BioPortfolio site is sponsored BioPortfolio Limited with offices at Stafford House, 10 Prince of Wales Road, Dorchester, DT1 1PW, England. If you are a legal copyright holder or a designated agent for such and you believe a post on this website falls outside the boundaries of “Fair Use” and legitimately infringes on your or your client's copyright we may be contacted concerning copyright matters at: priority@bioportfolio.com.
All rights reserved. All other trademarks recognized. Copyright © 1997-2018 BioPortfolio Limited. Site developed by Alacrify Ltd.